{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:13:35Z","timestamp":1789679615491,"version":"4.0.1"},"reference-count":0,"publisher":"Scientific Archives","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.scientificarchives.com\/about-us"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Haematol"],"abstract":"<jats:p>Background: Cutaneous T cell lymphoma (CTCL) is an incurable cancer characterized by elevated p38\u03b2 and p38\u03b3 and downregulated tumor-suppressive p38\u03b1.\n\nObjectives: We aimed to identify selective p38\u03b2 inhibitors and investigate their mechanisms and therapeutic implications in hematologic malignancies. \n\nMethods: A high-throughput screen of Food and Drug Administration (FDA)-approved compounds was conducted to identify p38\u03b2 inhibitors. In vitro kinase assays, Western blots, scRNA-seq, synergy tests, and mass spectrometry were used. Clinical trial and public datasets were analyzed.\n\nResults: Nilotinib was identified as a selective p38\u03b2 inhibitor (~25-fold over p38\u03b1). Its inhibition of p38\u03b2 led to compensatory activation of p38\u03b3, driving Epithelial-to-Mesenchymal Transition (EMT) and potential toxicities. Combining Nilotinib with p38\u03b3 inhibitors (e.g., CSH71 or Paclitaxel) produced synergistic anti-tumor effects in CTCL and leukemia cells. Clinical and FDA Adverse Event Reporting System (FAERS) data revealed higher toxicity rates for Nilotinib in Ph+ CML and off-target effects in non-CML cancers.\n\nConclusion: Nilotinib selectively inhibits p38\u03b2 but activates p38\u03b3, potentially reducing therapeutic selectivity. Combining it with p38\u03b3 inhibitors may enhance efficacy and reduce toxicity across hematologic malignancies.<\/jats:p>","DOI":"10.33696\/haematology.6.067","type":"journal-article","created":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:51:11Z","timestamp":1758397871000},"page":"38-55","source":"Crossref","is-referenced-by-count":3,"title":["Repurposing Nilotinib as a Selective P38\u03b2 Inhibitor in Hematopoietic Malignancies: Clinical Evidence and Mechanistic Insights"],"prefix":"10.33696","volume":"6","author":[{"given":"Xu Hannah","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Hsiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangkil","family":"Nam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yate-Ching","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Hmwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven T.","family":"Rosen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"18993","published-online":{"date-parts":[[2025]]},"container-title":["Journal of Clinical Haematology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:51:11Z","timestamp":1758397871000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.scientificarchives.com\/article\/repurposing-nilotinib-as-a-selective-p38b-inhibitor-in-hematopoietic-malignancies-clinical-evidence-and-mechanistic-insights"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.33696\/haematology.6.067","relation":{},"ISSN":["2766-4686"],"issn-type":[{"value":"2766-4686","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}